Glitazones: Could They Have a Rosy Future in Critical Care?

  • S. K. M. Marment
  • A. J. Semark
  • P. S. Kruger
Part of the Annual Update in Intensive Care and Emergency Medicine book series (AUICEM, volume 2012)

Abstract

The thiazolidinediones (glitazones) are drugs used in the management of diabetes. They are classified as synthetic selective peroxisome proliferator-activated receptor (PPAR) agonists and examples include rosiglitazone, pioglitazone, troglitazone and ciglitazone. The issues that have emerged around rosiglitazone and its cardiovascular side effects have dominated much of the discussion of these agents in the literature.

Keywords

Traumatic Brain Injury Spinal Cord Injury Adiponectin Level Plasmodium Falciparum Malaria Polymicrobial Sepsis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bell CM, Brener SS, Gunraj N, et al (2011) Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. JAMA 306: 840–847PubMedCrossRefGoogle Scholar
  2. 2.
    Kruger PS (2006) Statins: the next anti-endotoxin. Crit Care Resusc 8: 223–226PubMedGoogle Scholar
  3. 3.
    Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR (2011) The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J 32: 2525–2532PubMedCrossRefGoogle Scholar
  4. 4.
    Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC (2010) The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 33: 1859–1864PubMedCrossRefGoogle Scholar
  5. 5.
    Nathan DM, Buse JB, Davidson MB, et al (2009) Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32: 193–203PubMedCrossRefGoogle Scholar
  6. 6.
    DeFronzo RA, Tripathy D, Schwenke DC, et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364: 1104–1115PubMedCrossRefGoogle Scholar
  7. 7.
    DeFronzo RA, Abdul-Ghani M (2011) Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 34 (Suppl 2): S202–S209PubMedCrossRefGoogle Scholar
  8. 8.
    Kalaitzidis RG, Sarafidis PA, Bakris GL (2009) Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des 15: 529–536PubMedCrossRefGoogle Scholar
  9. 9.
    Hsiao A, Worrall DS, Olefsky JM, Subramaniam S (2004) Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 20: 3108–3127PubMedCrossRefGoogle Scholar
  10. 10.
    Tolman KG (2011) The safety of thiazolidinediones. Expert Opin Drug Saf 10: 419–428PubMedCrossRefGoogle Scholar
  11. 11.
    Dormandy JA, Charbonnel B, Eckland DJ, et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279–1289PubMedCrossRefGoogle Scholar
  12. 12.
    Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471PubMedCrossRefGoogle Scholar
  13. 13.
    Shah P, Mudaliar S (2010) Pioglitazone: side effect and safety profile. Expert Opin Drug Saf 9: 347–354PubMedCrossRefGoogle Scholar
  14. 14.
    Wilson KD, Li Z, Wagner R, et al (2008) Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality. PLoS One 3: e2609PubMedCrossRefGoogle Scholar
  15. 15.
    MacIsaac R, Jerums G (2004) Clinical Indications for thiazolidinediones. Australian Prescriber 27: 70–74Google Scholar
  16. 16.
    Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82–86PubMedCrossRefGoogle Scholar
  17. 17.
    Pierrakos C, Vincent JL (2010) Sepsis biomarkers: a review. Crit Care 14: R15PubMedCrossRefGoogle Scholar
  18. 18.
    Ghanim H, Garg R, Aljada A, et al (2001) Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 86: 1306–1312PubMedCrossRefGoogle Scholar
  19. 19.
    Wang N, Yin R, Liu Y, Mao G, Xi F (2011) Role of peroxisome proliferator-activated receptor-γ in atherosclerosis. Circ J 75: 528–535PubMedCrossRefGoogle Scholar
  20. 20.
    Sener G, Sehirli AO, Gedik N, Dulger GA (2007) Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs. Burns 33: 587–593PubMedCrossRefGoogle Scholar
  21. 21.
    Nicholls SJ, Tuzcu, EM, Wolski, K, et al (2011) Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J Am Coll Cardiol 57: 153–159PubMedCrossRefGoogle Scholar
  22. 22.
    Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2001) Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 507: 142–146PubMedCrossRefGoogle Scholar
  23. 23.
    Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2002) Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290: 1084–1089PubMedCrossRefGoogle Scholar
  24. 24.
    Lihn AS, Richelsen B, Pedersen SB, et al (2003) Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 285: E1072–1080PubMedGoogle Scholar
  25. 25.
    Coletta DK, Sriwijitkamol A, Wajcberg E, et al (2009) Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia 52: 723–732PubMedCrossRefGoogle Scholar
  26. 26.
    Robinson K, Kruger PS, Prins J, Venkatesh B (2011) The metabolic syndrome in critically ill patients. Best Pract Res Clin Endocrinol Metab 25: 835–845PubMedCrossRefGoogle Scholar
  27. 27.
    Yokota T, Oritani K, Takahashi I, et al (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96: 1723–1732PubMedGoogle Scholar
  28. 28.
    Ouchi N, Ohishi M, Kihara S, et al (2003) Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42: 231–234PubMedCrossRefGoogle Scholar
  29. 29.
    Hillenbrand A, Knippschild U, Weiss M, et al (2010) Sepsis induced changes of adipokines and cytokines — septic patients compared to morbidly obese patients. BMC Surg 10: 26PubMedCrossRefGoogle Scholar
  30. 30.
    Venkatesh B, Hickman I, Nisbet J, Cohen J, Prins J (2009) Changes in serum adiponectin concentrations in critical illness: a preliminary investigation. Crit Care 13: R105PubMedCrossRefGoogle Scholar
  31. 31.
    Koch A, Sanson E, Voigt S, et al (2011) Serum adiponectin upon admission to the intensive care unit may predict mortality in critically ill patients. J Crit Care 26: 166–174PubMedCrossRefGoogle Scholar
  32. 32.
    Galli A, Mello T, Ceni E, Surrenti E, Surrenti C (2006) The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin Investig Drugs 15: 1039–1049PubMedCrossRefGoogle Scholar
  33. 33.
    Raboud J, Diong C, Carr A, et al (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11: 39–50PubMedCrossRefGoogle Scholar
  34. 34.
    Wang W, Zhu Z, Zhu B, Ma Z (2010) Pioglitazone attenuates allergic inflammation and induces production of regulatory T lymphocytes. Am J Rhinol Allergy 24: 454–458PubMedCrossRefGoogle Scholar
  35. 35.
    Spears M, Donnelly I, Jolly L, et al (2009) Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther 86: 49–53PubMedCrossRefGoogle Scholar
  36. 36.
    Uji Y, Yamamoto H, Maeda K, et al (2010) Adiponectin deficiency promotes the production of inflammatory mediators while severely exacerbating hepatic injury in mice with polymicrobial sepsis. J Surg Res 161: 301–311PubMedCrossRefGoogle Scholar
  37. 37.
    Zingarelli B, Sheehan M, Hake PW, et al (2003) Peroxisome proliferator activator receptorgamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171: 6827–6837PubMedGoogle Scholar
  38. 38.
    Haraguchi G, Kosuge H, Maejima Y, et al (2008) Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. Intensive Care Med 34: 1304–1312PubMedCrossRefGoogle Scholar
  39. 39.
    Uji Y, Yamamoto H, Tsuchihashi H, et al (2009) Adiponectin deficiency is associated with severe polymicrobial sepsis, high inflammatory cytokine levels, and high mortality. Surgery 145: 550–557PubMedCrossRefGoogle Scholar
  40. 40.
    Wu WT, Lee CC, Lee CJ, et al (2011) Rosiglitazone ameliorates endotoxin-induced organ damage in conscious rats. Biol Res Nurs 13: 38–43PubMedCrossRefGoogle Scholar
  41. 41.
    Cuzzocrea S, Pisano B, Dugo L, et al (2004) Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 32: 457–466PubMedCrossRefGoogle Scholar
  42. 42.
    Kaplan JM, Denenberg A, Monaco M, et al (2010) Changes in peroxisome proliferatoractivated receptor-gamma activity in children with septic shock. Intensive Care Med 36: 123–130PubMedCrossRefGoogle Scholar
  43. 43.
    Schaller G, Kolodjaschna J, Pleiner J, et al (2008) Pioglitazone does not affect vascular or inflammatory responses after endotoxemia in humans. Horm Metab Res 40: 549–555PubMedCrossRefGoogle Scholar
  44. 44.
    Singh S, Loke YK, Furberg CD (2011) Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and metaanalysis. Thorax 66: 383–388PubMedCrossRefGoogle Scholar
  45. 45.
    Boggild AK, Krudsood S, Patel SN, et al (2009) Use of peroxisome proliferator-activated receptor γ agonists as adjunctive treatment for Plasmodium falciparum malaria: A randomized, double-blind, placebo-controlled trial. Clin Infect Dis 49: 841–849PubMedCrossRefGoogle Scholar
  46. 46.
    Kunz A, Dirnagl U, Mergenthaler P (2011) Acute pathophysiological processes after ischaemic and traumatic brain injury. Best Pract Res Clin Anaesthesiol 24: 495–509CrossRefGoogle Scholar
  47. 47.
    Yi JH, Park SW, Brooks N, Lang BT, Vemuganti R (2008) PPAR agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 1244: 164–172PubMedCrossRefGoogle Scholar
  48. 48.
    Sauerbeck A, Gao J, Readnower R, et al (2011) Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol 227: 128–135PubMedCrossRefGoogle Scholar
  49. 49.
    White AT, Murphy AN (2010) Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. J Neurochem 115: 845–853PubMedCrossRefGoogle Scholar
  50. 50.
    Park SW, Yi JH, Miranpuri G, et al (2007) Thiazolidinedione class of peroxisome proliferator-activated receptor agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 320: 1002–1012PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • S. K. M. Marment
  • A. J. Semark
  • P. S. Kruger

There are no affiliations available

Personalised recommendations